ClinicalTrials.gg
CompletedNCT04043104Updated Apr 24, 2023

A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia

A Phase 1 interventional study of AAV2hAQP1: 1 x 10^11 vg/gland (single gland) and AAV2hAQP1: 3 x 10^10 vg/gland (both glands) in Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy and Head and Neck Cancer, sponsored by MeiraGTx UK II Ltd. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-24.

Sponsored by MeiraGTx UK II Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 7 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Open-label, non-randomized, dose escalation trial of AAV2hAQP1 administered via Stensen's duct to a single or both parotid glands in subjects with radiation-induced xerostomia The objectives are to evaluate the safety and identify either a maximum tolerated dose or a maximum feasible dose of a single dose of AAV2hAQP1 infused into one or both parotid glands:

To evaluate subject improvement of xerostomia symptoms, to evaluate the increase in parotid gland salivary output after treatment with AAV2hAQP1, to evaluate additional efficacy outcomes.

02

Conditions studied

  • Radiation-Induced Parotid Gland Hypofunction
  • Xerostomia Due to Radiotherapy
  • Head and Neck Cancer
03

In context

Head and Neck Neoplasms

2,710 studies on the registry are indexed under Head and Neck Neoplasms; 594 are open to participants now.

This study's enrollment of 24 is below the median of 46 across 2,032 interventional studies indexed under Head and Neck Neoplasms.

Browse Head and Neck Neoplasms studies →

Lead sponsor

MeiraGTx UK II Ltd is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects ≥18 years of age.
  2. History of radiation therapy for head and neck cancer.
  3. Abnormal parotid gland function as judged by both absence of unstimulated parotid salivary flow and a stimulated parotid salivary flow in the targeted parotid gland >0 and \<0.3 mL/min/gland after 2% citrate stimulation.
  4. No evidence of recurrence of the primary by an otolaryngology (ears, nose, and throat [ENT]) assessment. Additionally, all subjects must be disease-free of head and neck cancer for at least 5 years following the end of treatment at screening, with the exception of subjects with a history of HPV+ OPC (base of tongue, oropharynx, pharynx, soft palate, tonsil) who must be disease free for at least 2 years following the end of treatment. Disease status will be determined by negative clinical examinations and computed tomography (CT) scans of the neck and chest. If subjects have had a magnetic resonance imaging (MRI) of the neck or a positron emission tomography (PET) scan within 6 months of screening, then a CT scan is not required, except for HPV+ OPC subjects who must have scans at 2 years post treatment.
  5. Female subjects of (i.e., ovulating, pre-menopausal, and not surgically sterile) and all male subjects must use a medically accepted regimen during their participation in the study and until all samples collected at 2 consecutive visits following AAV2hAQP1 administration are negative. Acceptable methods of contraception for male subjects include the following:

    • Condoms with spermicide. Acceptable methods of contraception for female subjects include the following:
    • Intrauterine device for at least 12 weeks prior to Screening.
    • Hormonal contraception (oral, implant, injection, ring, or patch) for at least 12 weeks prior to Screening.
    • Diaphragm used in combination with spermicide.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women or women planning to become pregnant.
  2. Any experimental therapy within 3 months before Day 1.
  3. Active infection that requires the use of intravenous antibiotics and does not resolve at least 1 week before Day 1.
  4. Uncontrolled ischemic heart disease (i.e., unstable angina, evidence of active ischemic heart disease on [ECG]).
  5. History of systemic diseases affecting the salivary glands.
  6. Use of systemic medications (i.e., ).

    o Note: Topical, inhaled, or intranasal corticosteroids are allowed.

  7. , other than head and neck cancer, within the past 3 years, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin or in situ cervical carcinoma.
  8. Active infections including, Epstein-Barr virus (EBV), cytomegalovirus (CMV), (HBV), (HCV), or (HIV) infection.
  9. White blood cell count \<3000/μL, \<1500/μL, \<10.0 g/dL, count \<100,000/μL, or absolute lymphocyte count ≤500/μL.
  10. and/or aspartate aminotransferase >1.5 × the (ULN), alkaline phosphatase >1.5 × ULN, or total >1.5 × ULN with any elevation of liver enzymes.
  11. Estimated \<60 mL/min/1.73 m2 using the Modification of Diet in Renal Disease equation.
  12. Active use of tobacco products as determined by self-reporting.
  13. Allergy to iodine or shellfish, and thus unable to have sialographic evaluations.
  14. Allergy or to glycopyrrolate.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1 x 10^11 vg/gland (single gland)

    Drug: AAV2hAQP1: 1 x 10^11 vg/gland (single gland)

  • Experimental
    3 x 10^10 vg/gland (both glands)

    Drug: AAV2hAQP1: 3 x 10^10 vg/gland (both glands)

  • Experimental
    3 x 10^11 vg/gland (single gland)

    Drug: AAV2hAQP1: 3 x 10^11 vg/gland (single gland)

  • Experimental
    1 x 10^11 vg/gland (both glands)

    Drug: AAV2hAQP1: 1 x 10^11 vg/gland (both glands)

  • Experimental
    1 x 10^12 vg/gland (single gland)

    Drug: AAV2hAQP1: 1 x 10^12 vg/gland (single gland)

  • Experimental
    3 x 10^11 vg/gland (both glands)

    Drug: AAV2hAQP1: 3 x 10^11 vg/gland (both glands)

  • Experimental
    3 x 10^12 vg/gland (single gland)

    Drug: AAV2hAQP1: 3 x 10^12 vg/gland (single gland)

  • Experimental
    1 x 10^12 vg/gland (both glands)

    Drug: AAV2hAQP1: 1 x 10^12 vg/gland (both glands)

Interventions

  • DrugAAV2hAQP1: 1 x 10^11 vg/gland (single gland)

    Drug page: Cetoquagene parvec

    Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland

  • DrugAAV2hAQP1: 3 x 10^10 vg/gland (both glands)

    Drug page: Cetoquagene parvec

    Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland

  • DrugAAV2hAQP1: 3 x 10^11 vg/gland (single gland)

    Drug page: Cetoquagene parvec

    Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland

  • DrugAAV2hAQP1: 1 x 10^11 vg/gland (both glands)

    Drug page: Cetoquagene parvec

    intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland

  • DrugAAV2hAQP1: 1 x 10^12 vg/gland (single gland)

    Drug page: Cetoquagene parvec

    Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland

  • DrugAAV2hAQP1: 3 x 10^11 vg/gland (both glands)

    Drug page: Cetoquagene parvec

    Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland

  • DrugAAV2hAQP1: 3 x 10^12 vg/gland (single gland)

    Drug page: Cetoquagene parvec

    Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland

  • DrugAAV2hAQP1: 1 x 10^12 vg/gland (both glands)

    Drug page: Cetoquagene parvec

    Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland

06

What researchers measure

Primary outcomes

  1. The primary outcome is safety of AAV2hAQP1 administered to the parotid gland of adult subjects with radiation-induced xerostomia

    Safety will be assessed by number of adverse events occurring with treatment

    Time frame: one day to one year

07

Study locations

6 sites
  • Leland Stanford Junior University
    Stanford, California 94305, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02184, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Atrium Health
    Charlotte, North Carolina 28209, United States
  • Health Sciences North - Northeast Cancer Center
    Sudbury, Ontario, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Mar 2023, 44 months.

Of 86 industry-sponsored phase 1 interventional studies under Head and Neck Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 44 months is close to that.

Counting every sponsor, half of 175 studies reached it within 45 months; a quarter within 31 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2019
First posted
Aug 2, 2019
StartActual
Jun 30, 2019
Primary completionActual
Mar 28, 2023
CompletionActual
Mar 28, 2023
Last update
Apr 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04043104
Lead sponsor
MeiraGTx UK II Ltd
Responsible party
Sponsor
First posted
Aug 2, 2019
Start date
Jun 30, 2019
Primary completion
Mar 28, 2023
Completion
Mar 28, 2023
Last update
Apr 24, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetoquagene parvec

Start the discussion